Composite Hydrogel Modified by IGF-1C Domain Improves Stem Cell Therapy for Limb Ischemia

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Vascular Biology

Background:

• Critical limb ischemia (CLI) treatment is limited by stem cell survival and function in ischemic environments.
• Biomimetic scaffolds can mimic stem cell niches to improve cell fate and therapeutic efficacy.
• Insulin-like growth factor 1 C-domain peptide (IGF-1C) is crucial for cell survival and function.

Purpose of the Study:

• To develop a bioactive hydrogel scaffold incorporating IGF-1C for enhanced adipose-derived stromal cell (ADSC) delivery.
• To evaluate the hydrogel's ability to improve ADSC survival, proangiogenic activity, and therapeutic potential in a mouse model of CLI.

Main Methods:

• Preparation of a chitosan-hyaluronic acid hydrogel immobilized with IGF-1C.
• In vitro assessment of ADSC viability and proangiogenic activity within the hydrogel.
• In vivo transplantation of ADSCs combined with the hydrogel into ischemic hind limbs of mice.
• Evaluation of therapeutic outcomes including blood perfusion, muscle regeneration, and fibrosis.

Main Results:

• IGF-1C-modified hydrogel significantly increased in vitro ADSC viability and proangiogenic potential.
• Co-transplantation of hydrogel and ADSCs improved blood perfusion and muscle regeneration in ischemic limbs.
• Enhanced ADSC retention, angiopoietin-1 secretion, and neovascularization were observed.
• Reduced inflammatory cell infiltration and collagen accumulation indicated antifibrotic effects.

Conclusions:

• The IGF-1C-modified composite hydrogel effectively promotes ADSC survival and enhances their therapeutic capacity for CLI.
• This biomimetic scaffold represents a promising strategy for cell-based regenerative therapies for critical limb ischemia.